ALLMedicine™ Gastrointestinal Tumors Center

Feb 13th, 2021 - Exosomes are polyvesicles that are formed by invagination of intracellular lysosomal particles, and are released into the extracellular matrix after the fusion of polyvesicular outer membrane and cell membrane. In the body, immune response, antige...

Feb 4th, 2021 - Endoscopic submucosal dissection (ESD) is a prominent minimally invasive operative technique for treating early gastrointestinal tumors but can result in postoperative bleeding. We conducted a randomized controlled trial to determine whether incre...

Feb 3rd, 2021 - The majority of gastrointestinal tumors are adenocarcinomas. Rarely, there are other types of tumors, such as acinar cell carcinoma, and these are often called pancreatic-type acinar cell carcinomas. Among these tumors, some are differentiated int...

Jan 20th, 2021 - Gastrointestinal cancers encompass a diverse class of tumors arising in the GI tract, including esophagus, stomach, pancreas and colorectum. Collectively, gastrointestinal cancers compose a high fraction of all cancer deaths, highlighting an unmet...

Jan 7th, 2021 - Oxygen saturation (OS) imaging is a new method of endoscopic imaging that has clinical applications in oncology which can directly measure tissue oxygen saturation (Sto2) of the surface of gastrointestinal tract without any additional drugs or dev...

Aug 13th, 2008 - Therapeutic endoscopy plays a major role in the management of gastrointestinal (GI) neoplasia. Its indications can be generalized into four broad categories; to remove or obliterate neoplastic lesion, to palliate malignant obstruction, or to treat...

Feb 13th, 2021 - Exosomes are polyvesicles that are formed by invagination of intracellular lysosomal particles, and are released into the extracellular matrix after the fusion of polyvesicular outer membrane and cell membrane. In the body, immune response, antige...

Feb 9th, 2021 - The invited discussant of the GARNET study, John C. Krauss, MD, Medical Oncology Director of the Multidisciplinary Colorectal Cancer Clinic, Rogel Cancer Center of the University of Michigan, Ann Arbor, observed that “impressive” response rates to...

Feb 9th, 2021 - Dostarlimab, a monoclonal antibody targeting PD-1, showed antitumor activity in patients with mismatch repair–deficient (dMMR) gastrointestinal tumors in the phase I GARNET study, reported at the 2021 Gastrointestinal Cancers Symposium by Thierry ...

Feb 4th, 2021 - Endoscopic submucosal dissection (ESD) is a prominent minimally invasive operative technique for treating early gastrointestinal tumors but can result in postoperative bleeding. We conducted a randomized controlled trial to determine whether incre...

Feb 3rd, 2021 - The majority of gastrointestinal tumors are adenocarcinomas. Rarely, there are other types of tumors, such as acinar cell carcinoma, and these are often called pancreatic-type acinar cell carcinomas. Among these tumors, some are differentiated int...

Sep 13th, 2020 - The use of immunotherapy for upper gastrointestinal tumors and renal cancer, ALK- and EGFR-targeted agents in non–small cell lunger cancer (NSCLC), and the next step in personalized prostate cancer management will all be subjects of headlining pre...

Sep 13th, 2020 - The use of immunotherapy for upper gastrointestinal tumors and renal cancer, ALK- and EGFR-targeted agents in non–small cell lunger cancer (NSCLC), and the next step in personalized prostate cancer management will all be subjects of headlining pre...

Sep 5th, 2018 - Hello. I'm David Kerr, professor of cancer medicine from University of Oxford. I'm never one not to be self-promoting. That's a gentle joke. Most of you are used to me talking about gastrointestinal tumors, but I wanted to stray into other areas b...

Apr 24th, 2018 - BOSTON – Endoscopic resection of gastrointestinal tumors arising from the muscularis propria is feasible, but the techniques are challenging and require a sure hand with closure techniques. “The main difficulty with these procedures is closure,” M.

Feb 28th, 2017 - (Reuters) - The U.S. Food and Drug Administration said on Tuesday it had approved Lexicon Pharmaceuticals Inc’s oral drug to treat carcinoid syndrome diarrhea, a condition that develops in patients with gastrointestinal tumors. The drug, Xermelo o...